Novogen Appoints Three New Directors
20 sept. 2010 08h00 HE
|
Novogen Limited
SYDNEY, AUSTRALIA--(Marketwire - September 20, 2010) - Pharmaceutical development company, Novogen Limited (ASX: NRT) (NASDAQ: NVGN) has appointed three new Directors.
Of the three...
Novogen Restructures Australian Management Team and Marshall Edwards Appoints CFO
18 juin 2010 09h00 HE
|
Novogen Limited
SYDNEY, AUSTRALIA--(Marketwire - June 18, 2010) - Novogen Limited's subsidiary, Marshall Edwards, Inc. (NASDAQ: MSHL), has announced today the appointment of Mr. Thomas Zech as its CFO and Company...
Marshall Edwards Announces Additional Management Changes With Appointment of New Chief Financial Officer
17 juin 2010 09h00 HE
|
Marshall Edwards, Inc.
SAN DIEGO, CA--(Marketwire - June 17, 2010) - Marshall Edwards, Inc. (NASDAQ: MSHL), an oncology company focused on the clinical development of novel anti-cancer therapeutics, announced today...
Marshall Edwards' CEO to Present at Needham Healthcare Conference
03 juin 2010 08h00 HE
|
Marshall Edwards, Inc.
SYDNEY, AUSTRALIA and SAN DIEGO, CA--(Marketwire - June 3, 2010) - Marshall Edwards, Inc. (NASDAQ: MSHL), an oncology company focused on the clinical development of novel anti-cancer...
Marshall Edwards Announces Final Results From Halted Phase 3 Clinical Trial of Phenoxodiol
01 juin 2010 08h31 HE
|
Marshall Edwards, Inc.
SYDNEY, AUSTRALIA and SAN DIEGO, CA--(Marketwire - June 1, 2010) - Marshall Edwards, Inc. (NASDAQ: MSHL), an oncology company focused on the clinical development of novel anti-cancer therapeutics,...
Report on Phase II Clinical Study of Marshall Edwards' Phenoxodiol in Prostate Cancer to Be Presented at ASCO
21 mai 2010 09h00 HE
|
Marshall Edwards, Inc.
SAN DIEGO, CA--(Marketwire - May 21, 2010) - Marshall Edwards, Inc., (NASDAQ: MSHL). An abstract titled "A phase II study of oral phenoxodiol in castrate and non-castrate prostate cancer...
Marshall Edwards Appoints New President and CEO
26 avr. 2010 08h00 HE
|
Marshall Edwards, Inc.
SYDNEY, AUSTRALIA and SAN DIEGO, CA--(Marketwire - April 26, 2010) - Marshall Edwards, Inc. (NASDAQ: MSHLD), an oncology company focused on the clinical development of novel anti-cancer therapeutics,...
Marshall Edwards, Inc. Announces Stockholder Approval and Implementation of 1:10 Reverse Stock Split
31 mars 2010 08h00 HE
|
Marshall Edwards, Inc.
NEW CANAAN, CT--(Marketwire - March 31, 2010) - Marshall Edwards, Inc. (NASDAQ: MSHL) (NASDAQ: MSHLD), a specialist oncology company focusing on the clinical development of novel anti-cancer...
Marshall Edwards, Inc. Appoints Acting CEO
01 déc. 2009 00h01 HE
|
Marshall Edwards, Inc.
SYDNEY, AUSTRALIA and NEW CANAAN, CT--(Marketwire - December 1, 2009) - Novogen Limited
advises that CEO and Managing Director Christopher Naughton will cease his
employment with the Company from...
Marshall Edwards Licenses the Investigational Anti-Cancer Compound NV-128 From Novogen Limited
05 août 2009 08h05 HE
|
Marshall Edwards, Inc.
NEW CANAAN, CT and SYDNEY, AUSTRALIA--(Marketwire - August 5, 2009) - Novogen Limited (ASX: NRT) (NASDAQ: NVGN) and Marshall Edwards, Inc. (NASDAQ: MSHL) have
concluded a license agreement for...